SITE003-0106

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2022-07-08

AEs

Serious

Dropout signal

–

Adverse events

moderate assessed

Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-07-25 (study day 10); relationship: N

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-10-11 (study day 88); relationship: not assessed

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-10-15 (study day 92); relationship: N

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-18 (study day 95); relationship: not assessed

severe assessed

Grade 3 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-10-31 (study day 108); relationship: Y

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-06 (study day 114); relationship: not assessed

moderate assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-11-21 (study day 129); relationship: N

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-12-24 (study day 162); relationship: not assessed

Data queries

No data queries.